九洲药业：关于公司收到化学原料药上市申请批准通知书的公告

Core Viewpoint - Jiuzhou Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Tofacitinib, indicating a significant milestone for the company in expanding its product portfolio [2] Group 1 - The company announced the receipt of the approval notice for Tofacitinib, with the notification number 2025YS01026 [2]